A patient who does not like insulin
Un paziente che non ama l’insulina
DOI:
https://doi.org/10.19156/abtpn.2018.0057Keywords:
Type 2 diabetes, Metastatic cancer, EGFR antagonist, Corticosteroid, EmpagliflozinAbstract
Hypoglycemic therapy over the past 20 years has expanded considerably with the use of new classes of more effective and safer medicines. Alongside the aging of the general population, the survival of diabetic subjects has significantly increased, thus exposing them to a greater risk of developing co-morbidities. This represents a challenge for the diabetologist, who must acquire ever broader concepts for the management of a complex and multi-organ disease. We report the case of a 72-year-old woman with type 2 diabetes mellitus and pulmonary adenocarcinoma of the right upper lobe with brain and bone metastases who, subjected to innovative and integrated treatments agreed between specialists of different disciplines, is still alive and free of cancer symptoms 23 months after diagnosis (Diabetology)
Downloads
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2018 The authors
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.